Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Ariad Pharmaceuticals (NasdaqNM:ARIA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Options | Financials
Location
26 Landsdowne Street
Cambridge, MA 02139
Phone: (617) 494-0400
Fax: (617) 494-8144
Email: investor@ariad.com
Employees (last reported count): 55
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 12%
·Institutional: 25% (28% of float)
(72 institutions)
·Net Inst. Buying: 1.60M shares (+17.57%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Ariad Pharmaceuticals, Inc. develops pharmaceutical product candidates based on small-molecule drugs and its proprietary gene regulation technology platforms. The Company integrates functional genomics and proteomics, protein engineering, and structure-based drug design in its drug discovery process. All of the Company's product candidates work through small-molecule regulation of cellular processes. Ariad currently has four development programs: a dual-action drug candidate for osteoporosis that both blocks bone resorption and stimulates bone formation; a drug candidate for cancer that blocks cell proliferation and tumor growth; a regulated cell therapy product candidate for graft-versus-host disease (GvHD) that selectively eliminates donor T-cells following allogeneic bone marrow transplantation (BMT), if they attack the patient's own tissues; and a protein therapy for anemia that provides precisely controlled erythropoietin production in vivo using an orally administered drug.
More from Market Guide: Expanded Business Description

Financial Summary
Ariad Pharmaceuticals is focused on the discovery and development of novel and proprietary drugs based on its understanding of the inner-workings of cells and the genes involved in disease. For the six months ended 6/30/01, revenues rose 6% to $935 thousand. Net loss rose 32% to $8.9 million. Revenues reflect higher interest income due to higher invested cash balances. Higher loss reflects higher product development costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Harvey Berger, M.D., 50
Chairman, Pres and CEO
$366K$432K
Sanford Smith, 53
Vice Chairman
--  --  
Lee Steele, 51
CFO, Sr. VP, Treasurer
--  --  
David Berstein, 48
Sr. VP and Chief Patent Counsel
203K1.5M
Fritz Casselman, 51
Sr. VP and CBO
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ARIAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$2.781
Recent Price$3.73 
52-Week High
on 5-Sep-2000
$15.875
Beta0.47 
Daily Volume (3-month avg)250.2K
Daily Volume (10-day avg)154.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-70.3%
52-Week Change
relative to S&P500
-60.2%
Share-Related Items
Market Capitalization$112.2M
Shares Outstanding30.1M
Float26.5M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.54 
Earnings (ttm)-$0.58 
Earnings (mrq)-$0.17 
Sales (ttm)$0.08 
Cash (mrq)$1.50 
Valuation Ratios
Price/Book (mrq)2.42 
Price/EarningsN/A 
Price/Sales (ttm)45.90 
Income Statements
Sales (ttm)$2.23M
EBITDA (ttm)-$13.5M
Income available to common (ttm)-$16.0M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-32.62%
Return on Equity (ttm)-37.88%
Financial Strength
Current Ratio (mrq)10.07 
Debt/Equity (mrq)0.09 
Total Cash (mrq)$45.3M
Short Interest
As of 8-Aug-2001
Shares Short1.13M
Percent of Float4.3%
Shares Short
(Prior Month)
1.11M
Short Ratio13.42 
Daily Volume84.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.